Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT+) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)

✍ Scribed by Lee, J.; Hays, J.; Noonan, A.; Annunziata, C.; Minasian, L.; Zujewski, J.; Houston, N.; Hearn, J.; Yu, M.; Kohn, E.

• Book ID: 125439200
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 57 KB
• Volume: 130
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2013.04.083